argenx
NEWS
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.
Here’s a run-down of some of the most recent collaboration announcements this week.
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
Argenx, based in Breda, the Netherlands, and Ghent, Belgium, announced positive topline results from its Phase III ADAPT clinical trial of efgartigimod for Myasthenia Gravis (MG).
Argenx, based in Breda, the Netherlands, and Halozyme Therapeutics, headquartered in San Diego, CA, signed a global collaboration and license deal that lets Argenx use Halozyme’s Enhanze drug delivery technology to develop multiple products.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it will share the detailed data from its Phase 2 clinical trial of efgartigimod (ARGX-113) in immune thrombocytopenia (ITP)
Argenx, based in Ghent, Belgium, announced a global collaboration and license deal with Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).
JOBS
IN THE PRESS